RELATED CONTENT
NEWS
- 2011 US submission for Genentech/Curis' vismodegib in basal cell carcinoma
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients
- Merck Serono ditches cladribine, leaving MS franchise exposed
- Industry views sought on EMA genomic biomarker consultation in drug development
COMMENT


